Christina H Wei1, Tristan R Gorgan, David A Elashoff, O Joe Hines, James J Farrell, Timothy R Donahue. 1. From the *Division of General Surgery, Department of Surgery, †Department of Statistics, ‡Jonsson Comprehensive Cancer Center, §Department of Medicine, Division of Digestive Disease, ∥Institute for Molecular Medicine, and ¶Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA.
Abstract
OBJECTIVES: The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings. METHODS: Meta-analyses were performed to calculate the pooled hazard ratios for each gene by each clinical outcome (overall survival [OS], disease-free survival [DFS], and progression-free survival) using a random-effects approach. RESULTS: The search strategy identified 16 eligible studies, composed of 632 PB patients total, with moderate quality. Compared with low expression, pooled hazard ratios for OS of hENT1, dCK, RRM1, RRM2, and DPD were 0.37 (95% confidence interval [CI], 0.28-0.47), 0.40 (95% CI, 0.20-0.80), 2.21 (95% CI, 1.12-4.36), 2.13 (95% CI, 1.00-4.52), and 1.91 (95% CI, 1.16-3.17), respectively. A similar trend was observed for each of these biomarkers in DFS and progression-free survival prognostication. Subgroup analyses for hENT1 showed a comparable survival correlation in the adjuvant and palliative settings. CONCLUSIONS: High expression of hENT1 in PB cancer patients receiving GEM-based adjuvant therapy is associated with improved OS and DFS and may be the best examined prognostic marker to date. Evidence for other biomarkers is limited by a small number of publications investigating these markers.
OBJECTIVES: The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancerpatients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings. METHODS: Meta-analyses were performed to calculate the pooled hazard ratios for each gene by each clinical outcome (overall survival [OS], disease-free survival [DFS], and progression-free survival) using a random-effects approach. RESULTS: The search strategy identified 16 eligible studies, composed of 632 PB patients total, with moderate quality. Compared with low expression, pooled hazard ratios for OS of hENT1, dCK, RRM1, RRM2, and DPD were 0.37 (95% confidence interval [CI], 0.28-0.47), 0.40 (95% CI, 0.20-0.80), 2.21 (95% CI, 1.12-4.36), 2.13 (95% CI, 1.00-4.52), and 1.91 (95% CI, 1.16-3.17), respectively. A similar trend was observed for each of these biomarkers in DFS and progression-free survival prognostication. Subgroup analyses for hENT1 showed a comparable survival correlation in the adjuvant and palliative settings. CONCLUSIONS: High expression of hENT1 in PB cancerpatients receiving GEM-based adjuvant therapy is associated with improved OS and DFS and may be the best examined prognostic marker to date. Evidence for other biomarkers is limited by a small number of publications investigating these markers.
Authors: Valeria Sebastiani; Francesca Ricci; Belen Rubio-Viqueira; Belen Rubio-Viquiera; Piotr Kulesza; Charles J Yeo; Manuel Hidalgo; Alison Klein; Daniel Laheru; Christine A Iacobuzio-Donahue Journal: Clin Cancer Res Date: 2006-04-15 Impact factor: 12.531
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Daniele Santini; Gaia Schiavon; Bruno Vincenzi; Carol E Cass; Enrico Vasile; Andrea D Manazza; Vincenzo Catalano; Giacomo Giulio Baldi; Raymond Lai; Sergio Rizzo; Alice Giacobino; Luigi Chiusa; Michele Caraglia; Antonio Russo; John Mackey; Alfredo Falcone; Giuseppe Tonini Journal: Curr Cancer Drug Targets Date: 2011-01 Impact factor: 3.428
Authors: Elisa Giovannetti; Niccola Funel; Godefridus J Peters; Marco Del Chiaro; Leyla A Erozenci; Enrico Vasile; Leticia G Leon; Luca E Pollina; Annemieke Groen; Alfredo Falcone; Romano Danesi; Daniela Campani; Henk M Verheul; Ugo Boggi Journal: Cancer Res Date: 2010-05-11 Impact factor: 12.701
Authors: Elisa Giovannetti; Mario Del Tacca; Valentina Mey; Niccola Funel; Sara Nannizzi; Sergio Ricci; Cinzia Orlandini; Ugo Boggi; Daniela Campani; Marco Del Chiaro; Mauro Iannopollo; Generoso Bevilacqua; Franco Mosca; Romano Danesi Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: James Russell; Nagavarakishore Pillarsetty; Robin M Kramer; Paul B Romesser; Pooja Desai; Adriana Haimovitz-Friedman; Maeve A Lowery; John L Humm Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488
Authors: Michael D Arensman; Donatello Telesca; Anna R Lay; Kathleen M Kershaw; Nanping Wu; Timothy R Donahue; David W Dawson Journal: Mol Cancer Ther Date: 2014-07-31 Impact factor: 6.261
Authors: Maria L Alvarellos; Jatinder Lamba; Katrin Sangkuhl; Caroline F Thorn; Liewei Wang; Daniel J Klein; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2014-11 Impact factor: 2.089